Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : sigx1094
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Signet Therapeutics Receives IND Approval for Targeted Therapy for Diffuse Gastric Cancer
Details : Sigx1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received IND approval from the FDA.
Brand Name : sigx1094
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2024
Lead Product(s) : sigx1094
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Epinephrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Juno Pharmaceuticals Pty Ltd
Deal Size : Undisclosed
Deal Type : Financing
Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.
Details : Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and sp...
Brand Name : Adrenaline Aguettant-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 24, 2022
Lead Product(s) : Epinephrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Juno Pharmaceuticals Pty Ltd
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
